SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication in Menopause: The Journal of The North ...
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced positive topline results from its Phase 1 clinical trial of ...
DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Daré ...
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly ...
The company prioritizes unmet needs for women in contraception, fertility, and vaginal and sexual health. Sabrina Martucci Johnson never planned on being a founder and CEO of a women’s healthcare ...
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly ...
DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results